Sept 23 (Reuters) - Boston Scientific Corp:
* Spirit IV results reaffirm strong performance of Boston Scientific Promus (R)
and Taxus (R) Express(R) stents
* Says results support benefits of paclitaxel-eluting stents in diabetic
patients
* On October 1 will begin its prior planned, phased discontinuation of Taxus
express stent used in spirit IV trial
* Says results showed the trial met its endpoint of TLF non-inferiority
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))
(For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
* Spirit IV results reaffirm strong performance of Boston Scientific Promus (R)
and Taxus (R) Express(R) stents
* Says results support benefits of paclitaxel-eluting stents in diabetic
patients
* On October 1 will begin its prior planned, phased discontinuation of Taxus
express stent used in spirit IV trial
* Says results showed the trial met its endpoint of TLF non-inferiority
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))
(For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.